Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anlotinib × anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5 Sarcoma 2 Neoplasm Metastasis 2 Endometrial Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Ovarian Neoplasms 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Gynecological Cancer 1 Glioblastoma 1 Craniopharyngioma 1 Carcinoma, Hepatocellular 1 Anlotinib 1 Adenocarcinoma of Lung 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04803851 2023-06-22

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Peking Union Medical College Hospital

Phase 1/2 Unknown

Gastrointestinal

Anlotinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡